filecrux
Oct 14, 11:27 AM
$ANGO AngioDynamics (vascular, cancer devices): Humana Medicare Advantage uses LCD L40205 for NanoKnife from Oct 1 in MACs lacking their own — only favorable intermediate-risk Grade Group 2 prostate cancer and colorectal liver metastases unfit for surgery or thermal ablation. NanoKnife sold
$8.3M in the quarter to Aug 31, up 29%, about 10% of
$80.9M sales; market value ~
$480M at the Oct 12 close, FY27 sales guidance
$336M-
$341M. Catch: prior authorization still applies, and it is one insurer. New CEO Eric Honroth starts Nov 2.
0 replies